@article{103985, keywords = {Scabies, Ivermectin, Mass drug administration, Solomon islands, Fiji, Prevalence}, author = {Andrews H and Lake S and Andersson S and Tavui A and Matavesi K and Koroivueta A and Koroivueta J and Vuniduvu R and Vuki M and Rosa V and Zinihite J and Tavalia J and Sosopu A and Huniehu J and Ghemu S and Rotu D and Parnaby M and Hughes T and Grobler A and Engelman D and Romani L and Tuicakau M and Kama M and Kaldor J and Sahukhan A and Sokana O and Steer A}, title = {Scabies and impetigo prevalence following ivermectin-based mass drug administration campaigns in Solomon Islands and Fiji}, abstract = {

Scabies is a neglected tropical skin disease that is endemic in Pacific Island countries. Ivermectin-based mass drug administration (MDA) trials have led to reductions in scabies and impetigo prevalence. The World Scabies Program supported ministries of health with national scabies MDA campaigns in Solomon Islands (two annual rounds, 2022–2024) and Fiji (one round, 2022). Here we conducted population-based national prevalence surveys before and after MDA in both countries to assess scabies and impetigo prevalence. We compared scabies and impetigo prevalence before MDA with the prevalence 6 to 12 months after. Over 9,000 participants were surveyed at each time point. In Solomon Islands, following two MDA rounds, scabies prevalence decreased from 23.2% to 3.9% while impetigo prevalence decreased from 9.2% to 1.6%. In Fiji, scabies prevalence decreased from 6.2% to 3.4% and that of impetigo decreased from 4.3% to 1.2%. We observed substantial reductions in the prevalence of scabies and impetigo following MDA in both countries, providing evidence to support similar large-scale scabies interventions.

}, year = {2026}, journal = {Nature Health}, pages = {1 - 22}, month = {07/2026}, publisher = {Springer Science and Business Media LLC}, issn = {3005-0693}, url = {https://www.nature.com/articles/s44360-026-00162-6.pdf}, doi = {10.1038/s44360-026-00162-6}, language = {ENG}, }